二尖瓣反流外科治疗的临床表现与结局:MITRACURE国际登记的真实世界洞察
MITRACURE是一项国际回顾性登记,纳入2019年法国和加拿大40个中心3522例因二尖瓣反流接受外科手术的成人患者。患者常晚期转诊,仅3%接受早期干预,总体修复率62%,院内死亡率4.5%。结果提示需改进管理策略。
要点
- 晚期表现常见:43%为NYHA III/IV级,30%有心衰,22%有肺动脉高压。
- 二尖瓣修复率总体62%,黏液样病变中80%。
- 院内死亡率总体4.5%,黏液样病变2.3%。
核心结论
- 患者常晚期转诊,早期干预极少,死亡率和修复率有改进空间。
研究设计与样本
- 国际回顾性登记,纳入2019年法国和加拿大40个中心3522例因二尖瓣反流接受孤立或联合二尖瓣手术的成人患者。
主要发现
- 最常见病因是黏液样(61%),其次功能性(9%)、感染性心内膜炎(9%)和风湿病(7%)。
- MR定量仅43%患者进行。
- 43%为NYHA III/IV级,30%有充血性心衰,47%使用利尿剂,22%有心房颤动/扑动,35%射血分数降低,22%有肺动脉高压(≥50 mm Hg)。
- 早期干预仅3%患者。
- 总体修复率62%,黏液样病变80%;院内死亡率总体4.5%,黏液样MR 2.3%(孤立1.8%,联合3.1%)。
临床怎么用
- 应关注MR患者晚期转诊问题,评估早期干预指征以提高修复率和降低死亡率。
局限性
- 回顾性登记设计,数据来自图表抽象和站点报告,可能存在选择偏倚和信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comprehensive knowledge of the clinical presentation, contemporary management, and outcomes on "all-comer" patients referred for mitral valve surgery (MVS) are critical to evaluate current practice and adherence to guidelines, understand selection biases, and inform key stakeholders on quality improvement. METHODS: MITRACURE is a large international retrospective registry of consecutive adult patients who underwent isolated or combined MVS for mitral regurgitation (MR) in France or Canada in 2019 with in-depth clinical and echocardiographic characterization. Patients operated on for isolated mitral stenosis or who had a prior mitral valve intervention were excluded. Data were obtained from detailed chart abstraction and were site reported. RESULTS: In 2019, 3522 patients underwent MVS (48% combined) across 40 centers (88±46 MVSs/center, median 80, interquartile [51-131]). Mean age was 65±12 years, and 35% were women. The most common MR etiology was myxomatous (61%), followed by functional (9%), infective endocarditis (9%), and rheumatic disease (7%). MR quantification was performed in only 43%. Advanced clinical presentation was common: 43% were in New York Heart Association class III/IV, 30% exhibited congestive heart failure, 47% were on diuretics, 22% had atrial fibrillation/flutter, 35% presented with reduced ejection fraction, and 22% had pulmonary hypertension (≥50 mm Hg). Most patients were symptomatic or presented with class I/IIa indication for intervention, and an early intervention was performed only in 3% of patients. The repair rate was 62% overall and 80% in myxomatous disease. In-hospital mortality was 4.5% overall but 2.3% in patients with myxomatous MR (1.8% isolated, 3.1% combined). CONCLUSIONS: MITRACURE provides a contemporary, multicenter, "real-world" picture of the clinical presentation, management, and in-hospital outcomes of MVS for MR in two Western countries. Patients were often referred late in the disease process, with few patients undergoing early intervention. The higher mortality and lower repair rates reported may be more reflective of an unselected MR patient population but have room for improvement. Our results underline the need to develop strategies to improve management and outcomes of patients with MR.
引用
- Messika-Zeitoun D, Chu MWA, Bouchard D, et al. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. Circulation. 2025. PMID: 40886109. doi:10.1161/CIRCULATIONAHA.124.073674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。